Pharsight

Drugs that contain Vemurafenib

1. Zelboraf patents expiration

ZELBORAF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8143271 HOFFMANN LA ROCHE NA
Jun, 2026

(2 years from now)

US7504509 HOFFMANN LA ROCHE Compounds and methods for development of Ret modulators
Oct, 2026

(2 years from now)

US7863288 HOFFMANN LA ROCHE NA
Jun, 2029

(5 years from now)

US8741920 HOFFMANN LA ROCHE Process for the manufacture of pharmaceutically active compounds
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470818 HOFFMANN LA ROCHE NA
Aug, 2026

(2 years from now)

US9447089 HOFFMANN LA ROCHE Compositions and uses thereof
Jun, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Market Authorisation Date: 17 August, 2011

Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as dete...

Dosage: TABLET;ORAL

More Information on Dosage

ZELBORAF family patents

Family Patents